Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer-Reference-Cited by-同舟云学术

Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer

Published:2021-07-29 Issue:5 Volume:385 Page:395-405
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Gnant Michael¹^ORCID,Fitzal Florian¹,Rinnerthaler Gabriel¹,Steger Guenther G.¹,Greil-Ressler Sigrun¹,Balic Marija¹,Heck Dietmar¹,Jakesz Raimund¹,Thaler Josef¹,Egle Daniel¹,Manfreda Diether¹,Bjelic-Radisic Vesna¹,Wieder Ursula¹,Singer Christian F.¹,Melbinger-Zeinitzer Elisabeth¹,Haslbauer Ferdinand¹,Sevelda Paul¹,Trapl Harald¹,Wette Viktor¹,Wimmer Kerstin¹,Gampenrieder Simon P.¹,Bartsch Rupert¹,Kacerovsky-Strobl Stephanie¹,Suppan Christoph¹,Brunner Christine¹,Deutschmann Christine¹,Soelkner Lidija¹,Fesl Christian¹,Greil Richard¹

Affiliation:

1. From the Comprehensive Cancer Center (M.G., C.F.S., C.D., F.F., K.W., S.K.-S.), the Department of General Surgery (F.F., K.W., S.K.-S.), the Department of Internal Medicine I, Division of Oncology (G.G.S., R.B.), and the Department of Obstetrics and Gynecology (C.F.S., C.D.), Medical University of Vienna, Austrian Breast and Colorectal Cancer Study Group (M.G., R.J., L.S., C.F.), Breast Care Center, Hanusch Hospital (U.W.), the Department of Gynecology, Hospital Hietzing, and Karl Landsteiner Institute...

Funder

AstraZeneca

ABCSG

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa2104162

Cited by 100 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world analysis of breast cancer patients qualifying for adjuvant CDK4/6 inhibitors;Clinical Breast Cancer;2024-08

2. Breast Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-07

3. Cancer cost-related subjective financial distress among breast cancer: a scoping review;Supportive Care in Cancer;2024-07

4. Epidemiology of early vs late recurrence among women with early stage estrogen receptor–positive breast cancer in the Pathways Study;JNCI: Journal of the National Cancer Institute;2024-06-06

5. Correlating Predicted Adjuvant Therapy Benefit and Risk of Recurrence Between Breast Cancer Index (BCI) and the 21-Gene Oncotype DX Recurrence Score (RS);Clinical Breast Cancer;2024-06